חוב לטווח קצר להון עצמי: Portage Biotech Inc (PRTG)

Portage Biotech Inc. (PRTG) is betting on iNKT inhibitors for systemic tumor destruction, which will enable high treatment costs due to inelastic demand. This daily price chart reflects the 0.02 metric. The biotech firm is currently cutting costs following a pause in testing, as it seeks partners or patent buyers. Meanwhile, its US and European base continues to develop combination immunotherapy through its drug portfolio.

Anticipating the results of mid-phase oncology drug trials requires strict liquidity control, which is why this chart of short-term liabilities to capital compares current borrowings of up to one year with equity, reflecting the dependence of Portage Biotech Inc. (PRTG) on operational financing; a decrease in this ratio confirms the effectiveness of resource conservation, minimizing refinancing risk and lowering the company's overall cost of capital.